Your browser doesn't support javascript.
loading
Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV).
Borradori, L; Van Beek, N; Feliciani, C; Tedbirt, B; Antiga, E; Bergman, R; Böckle, B C; Caproni, M; Caux, F; Chandran, N S; Cianchini, G; Daneshpazhooh, M; De, D; Didona, D; Di Zenzo, G M; Dmochowski, M; Drenovska, K; Ehrchen, J; Goebeler, M; Groves, R; Günther, C; Horvath, B; Hertl, M; Hofmann, S; Ioannides, D; Itzlinger-Monshi, B; Jedlicková, J; Kowalewski, C; Kridin, K; Lim, Y L; Marinovic, B; Marzano, A V; Mascaro, J-M; Meijer, J M; Murrell, D; Patsatsi, K; Pincelli, C; Prost, C; Rappersberger, K; Sárdy, M; Setterfield, J; Shahid, M; Sprecher, E; Tasanen, K; Uzun, S; Vassileva, S; Vestergaard, K; Vorobyev, A; Vujic, I; Wang, G.
Afiliação
  • Borradori L; Department of Dermatology, Inselspital, Bern University Hospital, Bern, Switzerland.
  • Van Beek N; Department of Dermatology, University of Lübeck, Lübeck, Germany.
  • Feliciani C; Dermatology Unit, Department of Medicine and Surgery, University Hospital, University of Parma, Italy.
  • Tedbirt B; Department of Dermatology, Rouen University Hospital, Referral Center for Autoimmune Bullous Diseases, Referral Center for Autoimmune Bullous Diseases, Rouen University Hospital, INSERM U1234, Normandie University, Rouen, France.
  • Antiga E; Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy.
  • Bergman R; Department of Dermatology, Rambam Health Care Campus, Haifa, Israel.
  • Böckle BC; Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
  • Caproni M; Department of Dermatology, Venereology & Allergology, Innsbruck Medical University, Innsbruck, Austria.
  • Caux F; Department of Health Sciences, Section of Dermatology, AUSL Toscana Centro, Rare Diseases Unit, European Reference Network-Skin Member, University of Florence, Italy.
  • Chandran NS; Department of Dermatology and Referral Center for Autoimmune Bullous Diseases, Groupe Hospitalier Paris Seine-Saint-Denis, AP-HP and University Paris 13, Bobigny, France.
  • Cianchini G; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Daneshpazhooh M; Department of Dermatology, Ospedale Classificato Cristo Re, Rome, Italy.
  • De D; Department of Dermatology, Autoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Didona D; Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Di Zenzo GM; Department of Dermatology and Allergology, Philipps University, Marburg, Germany.
  • Dmochowski M; Laboratory of Molecular and Cell Biology, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Rome, Italy.
  • Drenovska K; Autoimmune Blistering Dermatoses Section, Department of Dermatology, Poznan University of Medical Sciences, Poznan, Poland.
  • Ehrchen J; Department of Dermatology, Medical University of Sofia, Sofia, Bulgaria.
  • Goebeler M; Department of Dermatology, University of Münster, Münster, Germany.
  • Groves R; Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany.
  • Günther C; St. John's Institute of Dermatology, Viapath Analytics LLP, St. Thomas' Hospital, London, UK.
  • Horvath B; Division of Genetics and Molecular Medicine, King's College London, Guy's Hospital, London, UK.
  • Hertl M; Department of Dermatology, Carl Gustav Carus University Hospital, Technische Universität Dresden, Dresden, Germany.
  • Hofmann S; Department of Dermatology, Center for Blistering Diseases, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Ioannides D; Department of Dermatology and Allergology, Philipps University, Marburg, Germany.
  • Itzlinger-Monshi B; Department of Dermatology, Allergy and Dermatosurgery, Helios University Hospital Wuppertal, University Witten, Herdecke, Germany.
  • Jedlicková J; 1st Department of Dermatology-Venereology, Hospital of Skin and Venereal Diseases, Aristotle University Medical School, Thessaloniki, Greece.
  • Kowalewski C; Department of Dermatology, Venereology and Allergy, Clinical Center Landstrasse, Academic Teaching Hospital of the Medical University of Vienna, Vienna, Austria.
  • Kridin K; Medical Faculty, The Sigmund Freud Private University, Vienna, Austria.
  • Lim YL; Department of Dermatovenereology, Masaryk University, University Hospital St. Anna, Brno.
  • Marinovic B; Department of Dermatovenereology, University Hospital Brno, Brno, Czech Republic.
  • Marzano AV; Department Dermatology and Immunodermatology, Medical University of Warsaw, Warsaw, Poland.
  • Mascaro JM; National Skin Centre, Singapore, Singapore.
  • Meijer JM; Department of Dermatology and Venereology, School of Medicine, University Hospital Centre Zagreb, University of Zagreb, Zagreb, Croatia.
  • Murrell D; Dermatology Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Patsatsi K; Dermatology Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Pincelli C; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
  • Prost C; Department of Dermatology, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.
  • Rappersberger K; Department of Dermatology, Center for Blistering Diseases, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Sárdy M; Department of Dermatology, St George Hospital, University of New South Wales, Sydney, New South Wales, Australia.
  • Setterfield J; 2nd Department of Dermatology, Autoimmune Bullous Diseases Unit, Aristotle University School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece.
  • Shahid M; DermoLab, Institute of Dermatology, University of Modena and Reggio Emilia, Modena, Italy.
  • Sprecher E; Department of Dermatology and Referral Center for Autoimmune Bullous Diseases, Groupe Hospitalier Paris Seine-Saint-Denis, AP-HP and University Paris 13, Bobigny, France.
  • Tasanen K; Department of Dermatology, Venereology and Allergy, Clinical Center Landstrasse, Academic Teaching Hospital of the Medical University of Vienna, Vienna, Austria.
  • Uzun S; Medical Faculty, The Sigmund Freud Private University, Vienna, Austria.
  • Vassileva S; Abteilung Dermatologie, Venerologie und Allergologie, Lehrkrankenhaus der Medizinischen Universität Wien, Austria.
  • Vestergaard K; Department of Dermatology and Allergology, Ludwig Maximilian University, Munich, Germany.
  • Vorobyev A; Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary.
  • Vujic I; Department of Oral Medicine, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Wang G; Department of Dermatology, Medical University, Sofia, Bulgaria.
J Eur Acad Dermatol Venereol ; 36(10): 1689-1704, 2022 Oct.
Article em En | MEDLINE | ID: mdl-35766904
BACKGROUND: Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or, most frequently, generalized bullous lesions. A subset of patients only develops excoriations, prurigo-like lesions, and eczematous and/or urticarial erythematous lesions. The disease, which is significantly associated with neurological disorders, has high morbidity and severely impacts the quality of life. OBJECTIVES AND METHODOLOGY: The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology sought to update the guidelines for the management of BP based on new clinical information, and new evidence on diagnostic tools and interventions. The recommendations are either evidence-based or rely on expert opinion. The degree of consent among all task force members was included. RESULTS: Treatment depends on the severity of BP and patients' comorbidities. High-potency topical corticosteroids are recommended as the mainstay of treatment whenever possible. Oral prednisone at a dose of 0.5 mg/kg/day is a recommended alternative. In case of contraindications or resistance to corticosteroids, immunosuppressive therapies, such as methotrexate, azathioprine, mycophenolate mofetil or mycophenolate acid, may be recommended. The use of doxycycline and dapsone is controversial. They may be recommended, in particular, in patients with contraindications to oral corticosteroids. B-cell-depleting therapy and intravenous immunoglobulins may be considered in treatment-resistant cases. Omalizumab and dupilumab have recently shown promising results. The final version of the guideline was consented to by several patient organizations. CONCLUSIONS: The guidelines for the management of BP were updated. They summarize evidence- and expert-based recommendations useful in clinical practice.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Venereologia / Penfigoide Bolhoso / Dermatologia Idioma: En Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Venereologia / Penfigoide Bolhoso / Dermatologia Idioma: En Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suíça